RBC Capital analyst Gregory Renza downgraded Morphic (MORF) to Sector Perform from Outperform with a price target of $57, down from $70. The firm views the Eli Lilly (LLY) takeover price as “fair and solid.” With limited antitrust concerns, RBC expects the deal to close in Q3 as guided.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: